Opticann’s CB4 Relief-T are green-coloured oral softgel capsules, providing medical patients with a fast-acting, high-potency CBD option combined with a low dose of THC for an additive effect. They have 4x higher potency (based on peak absorption) and 3x faster onset (faster time to reach peak) versus most other oral CBD products.
CB4 Relief-T soft gels from Opticann contain 25mg of CBD, 13mg of beta-caryophyllene (BCP), and 0.75mg of THC per capsule. These three ingredients are reported to act on the cannabinoid receptors in the endocannabinoid system. Gluten-free, non-GMO formulation.
This product contains low levels of THC, which may result in a mild level of THC side effects, including drowsiness, dizziness, and dry mouth. These innovative CBD softgel capsules are formulated with patented VESIsorb® technology for increased and consistent bioavailability, offering maximum and safe CBD absorption when taken orally.
VESIsorb® is used to maintain the quality and stability of your medical cannabis.
Les gélules CB4 Relief-T d’Opticann contiennent chacune 25 mg de CBD, 13 mg de bêta-caryophyllène (BCP) et 0,75 mg de THC. Ces trois ingrédients agissent sur les récepteurs cannabinoïdes dans le système endocannabinoïde.
VESIsorbMD est une collection brevetée d’ingrédients naturels hydrosolubles utilisés par l’industrie pharmaceutique qui permettent de maintenir la qualité et la stabilité du produit.
L’absorption élevée des gélules CB4 Relief permet aux patients de prendre une seule dose une à deux fois par jour, le matin ou le soir, avec ou sans nourriture.
[]
Praesent feugiat tempor pulvinar. Maecenas ultrices mi augue, vitae volutpat libero tincidunt in. Morbi eu enim vehicula lectus efficitur vehicula et sed turpis. Maecenas tortor mauris, porta vitae eros mattis, semper vulputate purus. Quisque hendrerit ligula sed laoreet gravida. Mauris vel molestie dui.
Cannabis coverage for Veterans
Abba Vets
About Abba Medix
Blog
Healthcare Professionals
FAQ
Programs
Get prescribed
Register with Abba Medix
Contact us
Join our newsletter
